Yuanxin Technology

1.1 Identity, positioning, and the three-pillar model

Yuanxin Technology is legally Beijing Yuanxin Technology Group Co., Ltd., founded on 2015-03-20 and headquartered in Beijing's Fengtai District. The 2026 HKEX application proof is the cleanest identity anchor: it describes the group as China's largest full-chain service provider for innovative-drug commercialization by 2024 revenue and annual delivery value, with a business model that connects patients, pharmaceutical companies, healthcare professionals, hospitals, and insurers. In practical operating terms, the company runs three visible pillars. First is Miaoshou Doctor / Miaoshou Physician, an online medical and follow-up platform that complements hospital care with online consultations, repeat prescriptions, chronic-disease support, and home delivery. Second is Yuanxin Pharmacy, a hospital-adjacent offline-plus-online pharmacy network concentrated near tertiary hospitals and oriented toward innovative-drug dispensing rather than general convenience retail. Third is Yuanxin Huibao, an insurance-services and technology arm that designs, markets, administers, and settles commercial health-insurance products tied to innovative-drug access and patient affordability. The official group site reinforces this operating structure by exposing separate route pages for doctors, medical technology, pharmacy, Huibao insurance, service cases, and careers, while the Miaoshou site and app-store listings show a still-active patient product in 2026. The product architecture matters because Yuanxin is not only an online-consultation app competing for traffic. Its proposition is a closed loop: prescription outflow from hospitals, specialized fulfillment, patient management, payment coordination, and pharma-facing commercialization support. That makes the company structurally closer to an innovative-drug infrastructure platform than to a single-function telemedicine marketplace. It also explains why group disclosures emphasize pharmacies, insurers, and pharma customers at least as much as end-user consultation activity.[CO001, CO002, CO006, CO007, CO008, CO012]

1.2 Leadership, ownership, and capital base

Founder He Tao remains the key person. The prospectus identifies him as executive director, chairman, and chief executive officer, with prior leadership experience at J1.com/Guoda Jianyiwang and Shenzhen Sanjiu pharmacy operations. The rest of the disclosed operating bench is functionally aligned with Yuanxin's hybrid model: He Weizhuang oversees medical operations and user relations, Zhang Huanchang runs pharmaceutical retail, He Guofeng covers finance and investor relations as board secretary, and Wen Jing serves as CFO after a long PwC career. Non-executive representation from Tencent and HongShan/Sequoia China through Hao Rui and Zhou Kui shows that strategic and financial backers retain governance visibility. The 2026 filing says the board will comprise four executive, two non-executive, and three independent non-executive directors. Capital formation has been large by China digital-health standards. Official investor commentary from INCE Capital confirms the August 2021 Series F exceeded RMB 1.5 billion and included Sequoia, B Capital Group, OrbiMed, UOB, INCE Capital, and others after earlier D and E financings. Independent tracker pages such as InforCapital and VCBeat place cumulative funding around US$971 million / roughly RMB 5 billion across five major rounds, with the company in a pre-IPO stage. That broad investor set matters in two ways. It validates institutional appetite for Yuanxin's full-chain model, but it also means the company has carried private-market expectations for several years without completing an IPO. The 2026 application still presents a company with strong backers and visible governance, yet one whose public-market transition has proved harder than its fundraising history suggested.[CO003, CO004, CO005, CO021, CO022, CO024]

1.3 Scale, milestones, and adverse context

Operationally, Yuanxin reached meaningful scale by end-2025. The pharmacy network stood at 201 stores, 183 of them within one kilometer of hospitals, with 42,585 SKUs and broad coverage of innovative oncology and other innovative drugs approved since 2015. Miaoshou Physician averaged roughly 27 million monthly user visits in 2025. The insurance arm had served 230 insurers and 10 reinsurers, helped launch inclusive commercial health-insurance products in more than 180 cities, managed 246.6 million policies, and delivered related health-management services to about 4.8 million people. The marketing-services business had cumulatively served 506 pharmaceutical companies, covering 19 of China's top 20 domestic pharma companies and 19 of the top 20 global pharma companies by 2024 revenue, while healthcare-technology services had worked with 537 hospitals including more than 220 top-tier Class III Grade A institutions. Those scale markers sit inside a long milestone sequence. The company was founded in 2015, started out-of-hospital pharmacy services in late 2015, rolled out insurance services in 2018, launched pharma-marketing services in late 2019, and developed hospital technology services in 2019. Public-market ambition has been persistent: Sina's April 2026 recap says Yuanxin filed in October 2021, twice in 2022, twice in 2023, passed a Hong Kong hearing in February 2024, and returned for a sixth filing on 2026-04-22 with Huatai International as sole sponsor. The adverse signal is that persistence has come with reset economics. July 2026 critical coverage reported a 30% valuation haircut to RMB 19.5 billion, a drop in cash balances, and a reduction in self-owned pharmacies from 335 in 2023 to 201 in 2025. That does not negate the platform's real scale, but it does indicate that the path from ecosystem breadth to public-market quality remains incomplete.[CO008, CO009, CO010, CO011, CO012, CO014]

1.4 Exhibits

2.1 Market definition and boundaries

Yuanxin's addressable market is broader than telemedicine but narrower than 'all of digital health.' The relevant market starts with innovative-drug commercialization in China: getting specialty and oncology therapies prescribed, reimbursed, fulfilled, and supported outside the hospital when appropriate. That market overlaps with hospital-adjacent specialty pharmacy, internet follow-up care, hospital internet-hospital infrastructure, patient management, and commercial-insurance enablement. It does not include inpatient hospital revenue, drug discovery, manufacturing economics, or general consumer wellness. In other words, Yuanxin monetizes the handoff between diagnosis and durable treatment access rather than the entire healthcare spend stack. This market definition matters because broad digital-health TAM numbers can easily overstate what Yuanxin can actually capture. A general digital-health report counts wearables, software, health analytics, medical devices, and consumer apps; Yuanxin captures only the portion linked to prescription outflow, specialty fulfillment, insurer workflow, and pharma commercialization. Status-quo substitutes are still powerful: hospital pharmacies, traditional wholesalers, general e-commerce pharmacies, manual reimbursement processes, offline patient-assistance programs, and hospital-built internet portals. Yuanxin's edge is that it tries to connect all those fragments in a single workflow centered on innovative-drug access rather than offering just one point product.[CM001, CM002, CM003, CM023, CM029, CM035]

2.2 TAM, SAM, and practical sizing lenses

The highest-quality sizing lens comes from the Frost & Sullivan attachment included with Yuanxin's 2026 filing. It puts China's overall pharmaceutical market at RMB 1,629.7 billion in 2024 and RMB 2,129.7 billion in 2030, but the more relevant submarkets are growing faster. China's innovative-pharmaceutical market grew to RMB 309.9 billion in 2024 and is projected to reach RMB 606.5 billion by 2030, while the specialty-pharmacy market grew to RMB 102.7 billion in 2024 and is projected to reach RMB 219.4 billion by 2030. Frost explicitly ties this acceleration to prescription outflow, broader distribution beyond hospitals, faster reimbursement inclusion, and the first commercial health-insurance innovation-drug list. Within that framing, Yuanxin's practical SAM sits much closer to innovative-pharma access and specialty pharmacy than to all healthcare or even all digital health. Broader analyst estimates show why triangulation is necessary. IMARC says China's digital-health market reached USD 94.9 billion in 2025 and could reach USD 359.9 billion by 2034 at a 15.48% CAGR, while MRFR sizes China digital healthcare at only USD 16.5 billion in 2024 with a rise to USD 120.67 billion by 2035 at 19.83% CAGR. Those numbers are not directly contradictory so much as differently scoped: they package different mixes of telehealth, medical apps, health IT, wearables, analytics, and services. For Yuanxin, the better bottom-up anchor is the pharmacy-and-innovative-drug stack plus evidence from its own market position. Frost's ranking table shows Yuanxin at RMB 10.2 billion of 2024 revenue, RMB 4.8 billion of annual innovative-drug delivery value, and 237 self-owned specialty pharmacies, which indicates real share inside the specialty-fulfillment layer even if no public source precisely isolates its serviceable SOM.[CM004, CM005, CM006, CM007, CM008, CM009]

2.3 Buyer, user, payer, and adoption path

Yuanxin serves a multi-sided market, so the user is often not the budget owner. Patients use Miaoshou Doctor and Yuanxin pharmacies because they need convenient access to prescribed therapies, refills, affordability support, and follow-up services. Hospitals are institutional buyers for internet-hospital construction and workflow digitization, usually paying project-based service fees or integrating Yuanxin where prescription outflow and follow-up care need to extend beyond the hospital campus. Pharmaceutical companies buy commercialization services because innovative-drug uptake increasingly depends on out-of-hospital fulfillment, patient education, adherence support, and real-world follow-up rather than hospital stocking alone. Insurers and reinsurers are buyers of product design, claims, settlement, and health-management workflows because commercial coverage can bridge gaps left by the NRDL. The adoption path therefore moves through policy-enabled but operationally complex workflows. A patient is first diagnosed in a physical institution, receives follow-up and e-prescription support through licensed internet-medical workflows, fulfills through hospital-adjacent pharmacies or coordinated delivery, and then enters insurer or pharma-sponsored support programs where relevant. Yuanxin benefits when these actors all want the same thing: faster access to innovative therapy with lower friction. But each stakeholder has a different buying trigger. Hospitals care about compliance and workflow efficiency; insurers care about claims control and differentiated products; pharma companies care about commercialization reach; patients care about access and affordability; and doctors care about continuity of treatment. This complexity raises switching costs but also lengthens sales cycles and makes the market harder to summarize with one simple 'software TAM.'[CM023, CM024, CM025, CM026, CM027, CM028]

2.4 Growth drivers, adoption constraints, and contradictory estimates

The structural tailwinds are strong. Official policy since 2018 has allowed internet hospitals built on physical medical institutions, online follow-up for common and chronic disease, and e-prescriptions with pharmacist review and qualified delivery. Frost further highlights accelerated NRDL inclusion for innovative drugs, the rise of diversified distribution channels, prescription outflow, and the new commercial-insurance innovation-drug list as catalysts for the out-of-hospital specialty-drug ecosystem. MarketsandMarkets adds demand-side drivers: aging demographics, the urban-rural healthcare access gap, Healthy China 2030 policy support, and 5G-enabled remote care infrastructure. These all reinforce Yuanxin's logic that treatment access will increasingly be organized across hospitals, pharmacies, insurers, and digital services rather than inside one institution. The constraints are just as important. The 2019 internet-diagnosis rules prohibit first-diagnosis internet treatment and keep the market tied to licensed institutions, which caps pure online scale. A 2026 market commentary argues that telemedicine in China is now more of a consolidation story than a greenfield traffic land-grab, with surviving platforms monetizing medicine sales more than consultations. Yuanxin's own economics point in the same direction: even with large hospital and online footprints, its hospital-tech revenue remains small, while pharmacy and pharma-linked services dominate. Finally, analyst market-size estimates vary widely, so investors should treat broad digital-health CAGR numbers as context rather than valuation-ready inputs. The more credible thesis is that Yuanxin sits in one of the faster-growing subsegments of Chinese healthcare — innovative-drug access and specialty fulfillment — but captures that growth only if regulation, payer integration, and fulfillment execution keep working together.[CM016, CM017, CM018, CM019, CM020, CM021]

2.5 Exhibits

3.1 Competitive set and segmentation

Yuanxin should not be benchmarked against only one type of rival. Its model overlaps with at least four competitive clusters: consumer online-health platforms such as JD Health and Ping An Health; physician-content and pharma-marketing specialists such as Medlive and DXY; online chronic-disease / internet-hospital commerce players such as Fangzhou; and hospital-data or AI-adjacent companies such as Yidu Tech. WeDoctor remains a recognized Chinese online-health brand, but public source quality on its current business is weaker than for listed peers. Alibaba Health also matters because it combines broader consumer traffic, e-commerce capability, and healthcare services that can pressure pharmacy economics even when its model is not identical to Yuanxin's. This segmentation matters because Yuanxin's overlap with each competitor is partial. It is not the largest traffic platform, not the largest physician-media network, not the largest general health-retail marketplace, and not the clearest pure software story. Instead, it competes by stitching together prescription outflow, specialty dispensing, hospital collaboration, insurer enablement, and pharma commercialization. That makes some public comps directionally useful but imperfect. Investors should therefore compare Yuanxin along specific buying criteria — specialty-pharmacy density, hospital adjacency, insurer integration, pharma-service depth, and public-market readiness — rather than averaging broad 'digital health' peers together.[CP001, CP002, CP011, CP012, CP013, CP014]

3.2 Scaled platform competitors: JD Health, Ping An Health, Alibaba Health, and WeDoctor

JD Health is the most obvious scale benchmark. StockAnalysis' September 2026 snapshot shows RMB 79.04 billion of trailing-twelve-month revenue, 6,018 employees, and HKD 116.42 billion of market capitalization, while its company description highlights online medical consultation, referrals, health check-ups, internet healthcare, home-care services, and technical services. In practice JD Health competes with Yuanxin on consumer acquisition, online medical services, pharmacy commerce, and broad healthcare retail, but at a much larger scale and with JD ecosystem advantages. Alibaba Health is also formidable on platform distribution: StockAnalysis shows RMB 34.26 billion of annual revenue, 1,394 employees, and HKD 49.95 billion market capitalization, reinforcing that Yuanxin faces consumer and retail rivals backed by major internet ecosystems. Ping An Health is smaller than JD Health but more directly relevant as a healthcare-service platform with public disclosure quality. Its 2025 annual-results announcement reported RMB 5.468 billion of revenue and RMB 414 million of adjusted net profit, while StockAnalysis shows about 1,586 employees and HKD 13.87 billion of market capitalization. The company description emphasizes online diagnosis and treatment, consultations, health-management services, tests, and smart-device sales — a more service-led digital-health stack that overlaps with Yuanxin's online medical and payer-adjacent ambitions. WeDoctor remains strategically relevant as a long-known Chinese internet-health brand; a 2026 GetLatka profile places it at about US$423.6 million of revenue, US$1.5 billion total funding, a US$7 billion 2022 valuation, roughly 2,000 employees, and Hangzhou headquarters. But compared with listed peers, the available public evidence on WeDoctor is thinner and more tracker-dependent, which limits precision.[CP002, CP003, CP004, CP005, CP006, CP010]

3.3 Specialist and adjacent competitors: Medlive, DXY, Fangzhou, Yidu Tech

Medlive and DXY pressure Yuanxin from the professional side of the market. StockAnalysis describes Medlive as an online professional physician platform offering precision marketing, digital detailing, digital-marketing consultation, digital content creation, and software-development services to pharma customers. The same source shows RMB 645.32 million of trailing revenue, 724 employees, and HKD 5.66 billion of market capitalization, which implies that public investors still value physician-attention assets at a meaningfully higher sales multiple than drug-fulfillment businesses. DXY, meanwhile, is described by the World Economic Forum as a leading digital healthcare technology platform in China connecting hospitals, doctors, scientific researchers, patients, pharmaceutical companies, and insurers. It claims over 100 million public users and 5.5 million professional users and spans content, e-learning, online consultation, e-commerce, and offline primary care. That gives DXY broad reach into pharma marketing and physician engagement — areas where Yuanxin also sells services. Fangzhou is a closer transactional peer on the internet-hospital and chronic-disease side, though at smaller scale. StockAnalysis shows RMB 3.86 billion of trailing revenue, 494 employees, and only HKD 983.67 million of market capitalization, indicating that public investors are skeptical of this class of model when growth and profitability are not clearly established. Yidu Tech is less of a pharmacy rival and more of a hospital-data / AI-adjacent competitor, with RMB 819.30 million of annual revenue, 754 employees, and HKD 3.94 billion of market capitalization. Together these specialists illustrate the fragmentation of Yuanxin's battlefield: physician mindshare, hospital data, chronic-disease workflows, and digital commercialization are all separately contested, so Yuanxin needs ecosystem depth rather than just app traffic to defend itself.[CP007, CP008, CP009, CP012, CP013, CP019]

3.4 Yuanxin differentiation and moat risk

Yuanxin's core differentiation is not that it wins every consumer or physician metric; it is that it combines several hard-to-replicate interfaces in one operating loop. The 2026 prospectus and Frost attachment position it as the leading full-chain innovative-drug commercialization provider by 2024 revenue, while the company disclosed 201 pharmacies, 537 hospital collaborations, 230 insurers, 10 reinsurers, and 506 pharmaceutical-company customers by end-2025. Official site materials and the 2025 Pfizer upgrade article reinforce the same pattern: Yuanxin wants to be the connector between hospital discharge, specialty dispensing, patient management, insurance coordination, and pharma commercialization. That makes it structurally different from a pure physician-media company like Medlive, a content-network platform like DXY, or a general online-health marketplace like JD Health. The moat is real but not unassailable. JD, Alibaba, and Ping An can subsidize health services from larger ecosystems and enjoy better public-market credibility. Medlive and DXY may own more physician attention in specific workflows. Fangzhou shows how public markets can heavily discount internet-hospital and pharmacy models when profitability is uncertain. And Yuanxin's own repeated IPO filings indicate that its full-chain advantage has not yet translated into an uncontested capital-markets narrative. The practical read is that Yuanxin does have differentiated assets — hospital-adjacent pharmacies, insurer integration, and pharma partnerships — but moat durability depends on execution in those domains, not on trying to out-traffic the internet conglomerates.[CP014, CP015, CP016, CP022, CP023, CP024]

3.5 Exhibits

4.1 Revenue model and mix shift

Yuanxin's reported scale is much larger than most digital-health startups, but the revenue base is still dominated by physical drug fulfillment rather than software. The 2026 prospectus divides revenue into three blocks: commercialization fulfillment network, commercialization acceleration services, and healthcare technology services. Total revenue increased from RMB 9.737 billion in 2023 to RMB 10.205 billion in 2024 and RMB 10.377 billion in 2025, a decelerating path that implies roughly 4.8% growth in 2024 and only about 1.7% growth in 2025. The key change was mix. Out-of-hospital pharmacy and medical services rose from RMB 6.059 billion in 2023 to RMB 8.109 billion in 2025, growing from 62.2% to 78.1% of revenue, while wholesale pharmacy revenue fell from RMB 3.152 billion to RMB 1.636 billion and dropped from 32.4% to 15.8% of revenue. This is the most important financial story in the filing: Yuanxin is shrinking a low-margin wholesale layer and leaning more heavily into hospital-adjacent dispensing and related services. Below that core, commercialization acceleration services remained meaningful but still small. Insurance services moved from RMB 289.1 million in 2023 to RMB 334.9 million in 2025, while marketing services to pharmaceutical companies rose from RMB 186.5 million to RMB 214.1 million. Healthcare technology services grew from RMB 50.5 million to RMB 83.0 million, but still contributed only 0.8% of 2025 revenue. The official revenue-recognition notes explain why software-style valuation heuristics fit poorly: fulfillment revenue is recognized at point of sale or delivery, insurance revenue comes from commissions, service fees, or fixed fees tied to premium administration, and hospital-tech revenue is recognized when project services are fulfilled. This is a blended healthcare-services and distribution income statement, not a high-gross-margin pure SaaS model.[CI001, CI006, CI007, CI008, CI009, CI010]

4.2 Profitability and unit economics

The headline profitability trend improved materially in 2025 but remains fragile. Prospectus data show gross profit of RMB 911.2 million in 2023, RMB 793.9 million in 2024, and RMB 1,022.6 million in 2025, with gross margin moving from 9.4% to 7.8% and then back up to 9.9%. Net loss widened from RMB 719.0 million in 2023 to RMB 1,094.1 million in 2024 before narrowing sharply to RMB 400.9 million in 2025. The non-IFRS adjusted net loss moved from RMB 677.2 million in 2023 to RMB 939.0 million in 2024 and then to RMB 260.2 million in 2025, while adjusted EBITDA improved to negative RMB 52.0 million in 2025 from negative RMB 696.6 million in 2024. That is real operating repair, not just financial engineering, but it still leaves Yuanxin below breakeven after a decade of operating history. The 2024 deterioration is also informative. The prospectus says other expenses and losses rose to RMB 270.0 million in 2024 due largely to RMB 175.8 million of intangible-asset impairment, RMB 19.2 million of pharmacy shut-down losses, and RMB 18.2 million of fair-value changes on contingent consideration. At the same time, 2025 expense discipline was visible: selling and distribution fell to RMB 966.4 million from RMB 1.098 billion in 2024, administrative expense normalized back to RMB 297.3 million, and R&D declined to RMB 114.0 million. The adverse reading is that Yuanxin's unit economics are still structurally narrow. A 9.9% gross margin is better than 2024, but it remains far below software norms, which means sustainable profits depend on tighter opex and mix discipline rather than top-line growth alone.[CI002, CI003, CI004, CI005, CI012, CI013]

4.3 Liquidity and capital adequacy

Liquidity improved in one narrow sense and tightened in a broader one. Yuanxin generated positive operating cash flow of RMB 42.7 million in 2024 and RMB 138.2 million in 2025 after burning RMB 347.0 million in 2023. Yet investing cash outflow worsened to RMB 461.0 million in 2025, financing cash outflow remained negative, and the prospectus showed a RMB 402.9 million net decrease in cash and cash equivalents in 2025. Balance-sheet current assets show cash and cash equivalents of RMB 909.1 million at end-2023, RMB 531.0 million at end-2024, and RMB 329.3 million at end-2025, while trade and bills payables rose from RMB 1.293 billion to RMB 1.880 billion across the same period and deposits for guarantee rose from RMB 138.4 million to RMB 574.2 million. The filing itself warns that cash declined while trade and bills payable increased, contributing to pressure on net current assets. Independent July 2026 coverage makes the liquidity picture more acute. Shuziqushi emphasized that Yuanxin had not completed new external financing between 2022 and 2026, that store closures helped bring the network from 335 stores in 2023 to 201 in 2025, and that the company cut its pre-IPO valuation by 30% to RMB 19.5 billion. The article also highlighted a much lower year-end cash figure drawn from the cash-flow statement, underlining the need to reconcile cash definitions during diligence. Netting it all out, Yuanxin is not in immediate operational collapse — it has large revenue, positive operating cash flow, and active IPO plans — but it is operating with materially tighter capital headroom than a casual top-line reading might suggest.[CI017, CI018, CI019, CI020, CI021, CI022]

4.4 Public financial gaps and diligence priority

The most important missing pieces are not the top-line numbers; they are the economics underneath them. The prospectus does not publicly provide segment-level gross margins, store-level contribution margins, pharmacy payback periods, insurer-customer profitability, sales efficiency by business line, or concentration data for major hospital, insurer, and pharmaceutical customers. That means investors can see that the company is becoming less wholesale-heavy, but cannot yet see precisely how much margin is created by pharmacy fulfillment versus insurance services versus pharma commercialization. A similar limitation applies to the store base: the filing shows store-count reduction and hospital proximity, but not same-store sales, same-store margin, or closure economics. As a result, public-market readiness still rests on narrative more than fully auditable operating architecture. Late-stage investors can underwrite the direction of travel — less wholesale, better opex control, positive operating cash flow, smaller losses — but should treat the 2025 improvement as provisional until they obtain store cohorts, cohort-level patient economics, claims-linked insurer profitability, and customer concentration. Yuanxin's financial case is credible enough to justify an IPO attempt, yet incomplete enough that the key underwriting question remains margin durability rather than revenue scale.[CI030, CI035, CI036, CI037, CI038]

4.5 Exhibits

5.1 Product stack and modules

Yuanxin's visible product stack has four main modules. Miaoshou Doctor is the consumer and physician-facing internet-medical layer. Official materials say the product launched in 2017, holds an internet-hospital medical-practice license, and supports online consultation, follow-up prescriptions, and chronic-disease management. The Apple App Store description adds practical use cases: adding outpatient doctors for one-to-one follow-up, booking experts, online referral, medicine ordering, home delivery, medical-record management, and fast consultation. This is not just a triage app; it is a post-diagnosis continuity layer designed to keep the patient inside Yuanxin's medication and service loop. The second module is Yuanxin Pharmacy, the fulfillment layer. Official materials say that by 2025-12-31 the group operated 201 hospital-adjacent pharmacies across 27 provincial-level regions, focused on specialty therapeutic areas and supported by professional medication guidance, cold-chain delivery, and rapid local fulfillment. The third module is Yuanxin Medical Technology, which the group says it developed in 2019 to help hospitals — especially top-tier hospitals — digitize operations and support long-term patient management; by end-2025 it had collaborated with 537 hospitals. The fourth module is Yuanxin Huibao, the payment and protection layer, positioned as an 'insurance + medical + medicine' platform offering 惠民保险, drug insurance, health management, and claims investigation. Taken together, the product stack is designed to control the patient journey from diagnosis-adjacent access through reimbursement and refill support.[CE001, CE002, CE003, CE004, CE005, CE006]

5.2 Operating workflows and architecture

The platform architecture is workflow-centric rather than feature-centric. On the physician side, Miaoshou serves as a cloud clinic with online consultations, patient grouping, physician education, e-prescriptions, and access to professional drug services. On the institutional side, the same system exposes hospital tools for smart prescriptions, online diagnosis, and specialty-department enablement, while also offering pharma-facing patient recruitment and digital marketing. On the pharmacy side, Yuanxin's stores are not simple pickup points: they extend prescription verification, counseling, cold-chain delivery, and therapy-specific service. On the insurance side, Huibao supports product design, pricing, claims investigation, risk control, and health-management service scenes such as multidisciplinary consultation, video visits, genetic testing, and severe-disease support. The best public window into the deeper operating architecture is the Pfizer article from November 2025. It describes a graded DTP-pharmacy management system with basic pharmacies, professional pharmacies using the Yuanxin Patient Management Platform for record-keeping, follow-up, electronic medication histories, and automatic DOT generation, and research pharmacies connected to a specialized-disease database supporting real-world studies and investigator-initiated trials. The same article says AI tools and an intelligent-agent capability expand standardized service delivery and hospital-store collaboration. That combination — software workflows, structured patient-management data, and physical dispensing nodes — is the distinctive technical spine of the platform. It is also why the business is operationally complex: software only works here when it is tightly integrated with pharmacists, physicians, logistics, and insurers.[CE003, CE009, CE010, CE011, CE012, CE018]

5.3 Trust, compliance, and critical dependencies

Trust and compliance are central product attributes because Yuanxin operates in medication, prescriptions, and insurance rather than in low-stakes wellness. App-store disclosures explicitly warn that the service cannot replace in-person diagnosis and requires users to provide accurate follow-up information and appropriate revisit credentials. Official pages emphasize the platform's medical-practice license and its role in connecting 'doctor, patient, and medicine.' The pharmacy product similarly depends on medication-safety processes such as prescription review, professional pharmacist guidance, self-operated stores, and cold-chain integrity. Huibao's claims-investigation and risk-control positioning shows that insurance credibility is another core trust layer. These trust layers create real operating dependencies. The system relies on hospital integrations for compliant diagnosis and referral, pharmacists for specialty-drug review and counseling, reliable delivery for time- and temperature-sensitive medicines, insurers for payment expansion, and pharmaceutical partners for access and patient-support workflows. The platform is therefore not lightweight software. If regulation tightens, hospital collaboration weakens, or pharmacy standardization slips, product quality degrades quickly. That dependence cuts both ways: it raises execution risk, but it also creates a harder-to-replicate product moat than a standalone telemedicine app.[CE014, CE016, CE017, CE023, CE027, CE031]

5.4 Product maturity, roadmap, and benchmark pressure

The public roadmap is implicit rather than fully documented. The clearest milestones are the 2017 launch of Miaoshou Doctor, 2019 hospital-tech build-out, the November 2023 launch of the Yuanquan AI commercialization-fulfillment network and Huibao online insurance platform, and the 2025 public recognition as a Top 20 Chinese AI large-model commercialization company. The Apple App Store's 2026-04-30 update to version 6.4.40 shows the core consumer product is still maintained, while the Pfizer case suggests Yuanxin is trying to move beyond simple dispensing toward standardized, data-rich patient-management and research workflows. The logical maturity map is therefore: mature app and pharmacy operations, mature insurance workflows, growing hospital-tech capabilities, and early-stage AI overlays applied to process standardization and patient-management reach. Competitive product pressure is rising. Ping An's public 2024 Medtronic partnership described a '1-1-3-12' proactive health-management service system and whole-course chronic-disease management commitment, while a 2026 PRNewswire release framed AI healthcare empowerment as part of continued profitability improvement. JD Health's public description also includes home-care services, referrals, online consultations, and technical services. In other words, Yuanxin's front-end features are not unique. Its differentiation depends on integrating those front-end tools with DTP pharmacy grading, insurer workflows, and hospital-store linkage better than rivals. Publicly visible roadmap gaps remain significant: there is no detailed architecture disclosure, no uptime or integration metrics, and no module-level adoption disclosure, which means investors can see product breadth but not yet product efficiency.[CE009, CE010, CE019, CE020, CE021, CE022]

5.5 Exhibits

6.1 Customer segmentation and value proposition

Yuanxin's customer base is inherently multi-sided. Patients are the end users who need access to innovative drugs, specialist follow-up, refills, affordability support, and medication-management services. Hospitals are institutional customers and workflow anchors because diagnoses, prescription origination, and internet-hospital collaboration all begin there. Insurers and reinsurers buy or co-develop drug-protection, claims, and health-management services. Pharmaceutical companies buy commercialization acceleration, patient recruitment, patient-management, and real-world-research support. Physicians are both product users and channel enablers. The official site summarizes this well: the group delivers value to patients, doctors, hospitals, pharmaceutical companies, and insurance companies rather than to a single customer type. The value proposition also differs by segment. For patients, the pitch is access, convenience, and financial relief; for hospitals, it is smarter workflows and long-term patient management; for insurers, it is product design, pricing, claims, and risk control; for pharma companies, it is commercialization, patient recruitment, and follow-up. That means Yuanxin should be understood as a B2B2C platform whose consumer traffic matters, but whose economics rely heavily on enterprise and partner relationships. The customer question is therefore not just 'how many users does the app have?' but whether these interlocking segments reinforce each other enough to sustain repeat usage and budget renewals.[CU001, CU002, CU003, CU010, CU011, CU012]

6.2 Customer scale and adoption trajectory

The 2026 prospectus provides unusually broad scale disclosures for a private Chinese healthcare platform. Miaoshou Physician averaged about 27 million monthly visits in 2025. Yuanxin Pharmacy operated 201 hospital-adjacent stores across 27 provincial-level regions by 2025-12-31 and collaborated with 537 hospitals, including more than 220 top-tier Class III Grade A hospitals. On the payer side, Yuanxin had served 230 insurance companies and 10 reinsurance companies, managed 246.6 million policies since 2018, and served about 4.8 million people through health-management services. On the pharma side, it had cumulatively served 506 pharmaceutical companies, covering 19 of the top 20 domestic pharma companies in China and 19 of the top 20 global pharma companies by 2024 revenue. Those scale metrics should be read carefully. Policy counts are cumulative and not equivalent to active covered lives or revenue per customer. Similarly, 27 million monthly visits are traffic, not paid subscribers. Still, the breadth of adoption across customer classes is notable: relatively few digital-health platforms can point simultaneously to large patient traffic, broad hospital collaboration, wide insurer coverage, and hundreds of pharma-company relationships. The adoption story also appears cumulative rather than viral. Customers are acquired through hospital adjacency, insurer product launches, pharmacy presence, and commercialization partnerships more than through pure direct-to-consumer growth alone.[CU004, CU005, CU006, CU007, CU008, CU009]

6.3 Named customer proof and repeat-usage loops

Public customer proof is strongest where Yuanxin discloses named partners rather than anonymous counts. The prospectus milestone table says the company launched its first medical insurance product in December 2018 in cooperation with Taiping Life Insurance. In October 2025, the prospectus also says Yuanxin entered a real-world research collaboration agreement with the National Healthcare Security Institute of Capital Medical University. The November 2025 Pfizer article goes further, describing Yuanxin as a long-term ecological partner of Pfizer China and detailing a new phase of cooperation around DTP pharmacy grading, hospital-store linkage, and patient-management workflows. These named examples matter because they show Yuanxin selling into real counterparties across insurer, research, and pharma categories rather than only publishing aggregate counts. Repeat-usage logic is also embedded in the workflow. Chronic-disease management, follow-up prescriptions, electronic medication histories, health-management services, insurance claims assistance, and patient grouping all imply recurring interaction rather than one-off transactions. Official pages explicitly present Miaoshou as a post-visit management tool, Huibao as a continuing health-management and claims platform, and the pharmacy network as a local medication network for ongoing use. The right retention lens therefore is not traditional consumer-app DAU/MAU alone, but repeat prescription capture, therapy-course continuity, insurer service renewal, and pharma-program expansion. Unfortunately those deeper retention metrics are not public.[CU016, CU017, CU018, CU019, CU020, CU021]

6.4 Expansion, concentration risk, and diligence gaps

Customer diversification is a strength in theory, but it is not the same thing as low concentration risk in practice. Yuanxin discloses hundreds of hospitals, insurers, and pharma companies, yet does not publish segment-level revenue concentration, top-customer exposure, renewal rates, or satisfaction metrics such as NPS. That means investors do not know whether a small number of insurers, pharma programs, or hospital clusters contribute a large share of revenue. Nor do they know how much of the 4.8 million health-management population is active, how often prescriptions repeat, or whether enterprise accounts expand over time. There are also category-specific risks. Hospital-origin prescription flow remains a gatekeeper dependency. Insurance-product scale is meaningful, but Yuanxin does not underwrite the products and therefore depends on insurer appetite and partner economics. Pharma customer breadth is impressive, yet the durability of those relationships depends on commercialization ROI and compliance. The filing and official pages show a well-developed customer machine; what they do not show is the quality of those customer cohorts. That is the main diligence gap for this chapter.[CU022, CU023, CU024, CU025, CU026, CU027]

6.5 Exhibits

7.1 Regulatory and legal risk register

Yuanxin operates in one of the most regulated parts of Chinese digital services: online medicine, prescriptions, specialty drug fulfillment, health-insurance workflows, medical data, and commercialization support for pharmaceuticals. The core internet-medical rules are already restrictive. The 2018 State Council opinion and 2019 trial measures allow internet hospitals and online follow-up for common and chronic disease, but require licensed medical institutions, registered physicians, pharmacist review, and traceable data; they also prohibit first-diagnosis internet treatment. For Yuanxin, these rules are not background noise — they shape the product itself. Any tightening on follow-up prescriptions, drug delivery, or institution eligibility would hit core workflows directly. The compliance surface is widening in 2026. Legal and policy commentary from Arnold & Porter, Chambers, ICLG, Global Legal Insights, and others points to stronger enforcement around pharmaceutical anti-corruption, insurance-fund fraud, medical data, and AI/medical-software governance. The 2026 drug-regulation revision described by Cisema frames China as moving toward full-lifecycle oversight of drugs and digital supply chains, while privacy-law commentary highlights the strict interaction of the Data Security Law and Personal Information Protection Law for sensitive health data. Together, these raise both direct legal risk and operational cost. Yuanxin's integrated model only works if it keeps clinical, pharmacy, insurer, and data-compliance obligations aligned at all times.[CR008, CR009, CR010, CR011, CR012, CR013]

7.2 Operational, quality, and security risk register

Operationally, Yuanxin is exposed to the problems of both a pharmacy network and a digital platform. The prospectus and official pages show dependencies on prescription review, professional counseling, cold-chain delivery, self-operated stores, patient-management systems, claims handling, and hospital-store linkage. A failure in any of those layers can affect patient outcomes and regulator trust at the same time. This is a more demanding risk profile than a lightweight healthcare app. The platform also depends on secure handling of patient medical records, insurance data, and medication histories — precisely the categories that Chinese privacy and data-security enforcement treats as sensitive. The 2025-2026 financial and operational signals show why this matters. Yuanxin cut store count from 335 in 2023 to 201 in 2025, incurred pharmacy shut-down losses, and still operated at sub-10% gross margins in a business that requires physical service quality. The company has public AI ambitions, but its AI deployment is tied to regulated human workflows rather than replaceable consumer chat. That means classic AI risks such as data quality, model drift, or inaccurate recommendations are layered on top of medical, pharmacy, and insurance execution risks rather than substituting for them. A serious quality, privacy, or logistics failure could spread quickly across multiple business lines.[CR003, CR004, CR006, CR012, CR016, CR022]

7.3 Partner, dependency, and people / execution risk

Yuanxin's model depends on counterparties it does not fully control. Hospital-origin prescriptions are the top-of-funnel engine for pharmacy and follow-up activity. Insurers underwrite the products Yuanxin markets and services, so payer appetite and claims economics matter. Pharmaceutical companies fund commercialization and patient-support programs, which exposes Yuanxin to ROI scrutiny, anti-corruption enforcement, and the risk of budget shifts. Supplier dependence is also rising: adverse July 2026 coverage said the top five suppliers accounted for 53.7% of purchases in 2025 versus 40.4% in 2023. If supplier terms tighten, product availability changes, or partner programs slow, Yuanxin's economics can weaken quickly. There is also nontrivial execution and key-person risk. He Tao remains central to strategy, capital markets, and partner credibility, while different deputies oversee medical operations, finance, and retail execution. Repeated IPO filings show persistence but also execution drag. Workforce optimization and lower R&D spend helped the 2025 numbers, yet cost-cutting in a compliance-heavy service business can backfire if it weakens service quality or slows system development. The existence of stronger public competitors such as Ping An and JD means Yuanxin must keep executing across product, pharmacy, payer, and partner workflows simultaneously; it does not have room for a simple single-metric turnaround.[CR001, CR002, CR005, CR007, CR017, CR018]

7.4 Mitigation and kill criteria

The mitigation case is not empty. Yuanxin has real licenses, deep hospital adjacency, insurer and pharma breadth, and a patient-management architecture that can create switching friction. The company has also already demonstrated one important corrective action: it reduced wholesale exposure and moved operating cash flow positive in 2025. But those are mitigants, not proof that the business is out of danger. The right underwriting posture is to define kill criteria clearly: if liquidity keeps shrinking and an IPO or financing does not materialize; if regulation materially narrows e-prescription or online follow-up scope; if same-store pharmacy productivity disappoints; if insurer, hospital, or pharma renewal quality weakens; or if a material data/privacy incident occurs, the bull case should be revisited quickly. This matters because Yuanxin's risk transmission is cross-functional. A policy change can reduce prescription flow, which weakens pharmacy throughput, which hurts patient access, which lowers insurer and pharma value, which worsens cash generation. Conversely, better standardization, data governance, and partner-retention visibility could materially de-risk the asset. The burden of proof is on Yuanxin to show that its integrated model is resilient under tighter liquidity and tighter regulation, not just that it can tell a large-market growth story.[CR030, CR031, CR032, CR035]

7.5 Exhibits

8.1 Recommendation and entry discipline

Yuanxin deserves active tracking because the business has real operating scale, not just startup storytelling. The 2026 Hong Kong application proof and independent summaries show 2025 revenue of RMB 10.377 billion, 201 pharmacies, roughly 27 million average monthly Miaoshou Doctor visits, 230 insurers plus 10 reinsurers, 506 pharmaceutical-company customers, and 537 hospitals served through medical-technology workflows. That is unusually broad infrastructure for a private Chinese healthtech platform. It is also why the company remains relevant even after multiple failed listing cycles: very few peers combine patient access, specialty pharmacy, insurance enablement, and pharma commercialization services at this scale. But valuation discipline matters more than admiration. The July 2026 adverse reporting tied to the latest prospectus says Yuanxin cut its implied valuation by 30% to RMB 19.5 billion. Against 2025 revenue, that implies roughly 1.9x price-to-sales. On a superficial reading that looks lower than many software-style healthtech names. On a harder reading, it is a demanding price for a company with only 1.7% revenue growth in 2025, a 9.9% gross margin, a RMB 400.9 million net loss, sharply lower cash, and an IPO that has still not cleared after six filings. The right public-evidence posture is therefore track: the asset quality is real, but the disclosed price does not yet leave a clear margin of safety.[CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Thesis, anti-thesis, and comparable lenses

The positive thesis starts with structure. Frost & Sullivan's attachment to the HKEX filing ranks Yuanxin first among China's full-chain innovative-drug commercialization service providers by 2024 total revenue and puts the company at RMB 10.2 billion of 2024 revenue with 237 self-owned specialty pharmacies. The same materials frame a specialty-pharmacy market growing from RMB 102.7 billion in 2024 to RMB 219.4 billion in 2030 and an innovative-pharmaceutical market growing from RMB 309.9 billion to RMB 606.5 billion over the same period. Combined with Yuanxin's insurer, hospital, and pharma breadth, that supports a real platform thesis rather than a single-product trade. The anti-thesis is that the quoted pre-IPO mark already asks investors to look through several unresolved problems. Public market peers show widely different revenue multiples depending on business mix: JD Health and Alibaba Health screen around 1.28x trailing sales, Ping An Healthcare around 2.20x, Fangzhou 0.22x, Yidu 4.23x, and Medlive 7.60x. Yuanxin's implied 1.9x multiple sits below software-and-data names, but above broader low-margin pharmacy/distribution platforms that are already public and profitable. That means the company is not obviously undervalued simply because it is private and later-stage. The multiple only works if investors believe Yuanxin can convert scale into better margins, cleaner disclosure, and eventually public-market credibility.[CV010, CV012, CV013, CV014, CV015, CV016]

8.3 Bull, base, and bear scenario logic

Because Yuanxin's current public price anchor is a headline pre-IPO mark rather than a completed financing or market-clearing IPO, scenario analysis should be expressed as valuation bands tied to revenue multiples and underwriting assumptions. A bear case values the company around 1.0x-1.2x 2025 revenue, or roughly RMB 10.4-12.5 billion. That outcome would fit a world where growth stays near low single digits, cash remains tight, the public market keeps treating Yuanxin primarily as a low-margin pharmacy-access operator, or a new round prices below the current filing mark. The base case uses roughly 1.4x-1.9x revenue, or RMB 14.5-19.7 billion. That range gives Yuanxin credit for true scale, category leadership in innovative-drug commercialization, and the possibility that pharmacy mix and insurer/pharma workflows keep improving after the wholesale pullback. It also keeps a discount versus software-like names because public data still do not prove durable high-margin economics. The bull case requires 2.0x-2.6x revenue, or RMB 20.8-27.0 billion, which would only be justified if Yuanxin demonstrates better same-store pharmacy productivity, partner renewals, margin expansion, and a clean IPO path. In other words, public evidence can support a trackable base case, but not a buy-grade upside case yet.[CV011, CV023, CV024, CV025, CV026, CV032]

8.4 Exit readiness and final diligence asks

Yuanxin is closer to exit readiness than an early-stage healthtech startup, but still short of investable clarity. The repeated Hong Kong applications show management persistence and documentation depth, yet they also show that the market has not accepted the story on offered terms. The biggest missing variable is not the existence of a business; it is the quality of the earnings bridge from today's scaled but thin-margin model to a public-company profile with more resilient free cash generation. Investors still need the exact cap table and liquidation preferences, same-store pharmacy cohorts after store rationalization, contract-renewal quality with insurers and pharma companies, and segment-level contribution margins that isolate the economics of higher-value commercialization services from lower-margin drug distribution. Those asks are not academic. If a future financing or IPO prices below RMB 19.5 billion, or requires heavy preference protection, common-equity upside could compress sharply even if the company keeps growing. Conversely, if due diligence reveals strong renewal rates, genuine margin lift, and clean governance, the current headline mark could move from stretched toward fair. The final call is therefore track with medium confidence: Yuanxin has enough strategic relevance to follow closely, but not enough disclosed valuation support to recommend chasing the current implied entry price.[CV001, CV008, CV028, CV029, CV030, CV031]

8.5 Exhibits